Wall Street analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will post sales of $16.45 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Theravance Biopharma’s earnings, with the highest sales estimate coming in at $19.44 million and the lowest estimate coming in at $13.90 million. Theravance Biopharma posted sales of $8.32 million during the same quarter last year, which indicates a positive year over year growth rate of 97.7%. The firm is expected to issue its next earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Theravance Biopharma will report full year sales of $67.86 million for the current year, with estimates ranging from $65.00 million to $69.70 million. For the next fiscal year, analysts anticipate that the company will post sales of $117.40 million, with estimates ranging from $105.00 million to $129.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Theravance Biopharma.

Several brokerages have commented on TBPH. BidaskClub raised Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 10th. Zacks Investment Research lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. ValuEngine cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 22nd. Finally, Cantor Fitzgerald assumed coverage on shares of Theravance Biopharma in a research note on Monday, January 28th. They issued a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Theravance Biopharma has a consensus rating of “Hold” and an average target price of $43.40.

Shares of Theravance Biopharma stock traded down $0.37 on Friday, reaching $24.13. 194 shares of the stock were exchanged, compared to its average volume of 263,772. The company has a market cap of $1.37 billion, a PE ratio of -6.07 and a beta of 1.68. Theravance Biopharma has a one year low of $21.04 and a one year high of $35.48.

In other news, SVP Sharathchandra S. Hegde sold 9,033 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $24.71, for a total transaction of $223,205.43. Following the sale, the senior vice president now directly owns 270,134 shares in the company, valued at $6,675,011.14. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.60% of the company’s stock.

A number of large investors have recently made changes to their positions in TBPH. Amundi Pioneer Asset Management Inc. raised its holdings in Theravance Biopharma by 34.1% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 1,400 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Theravance Biopharma in the 4th quarter valued at $42,000. Virtus ETF Advisers LLC lifted its position in shares of Theravance Biopharma by 7.2% during the 3rd quarter. Virtus ETF Advisers LLC now owns 32,226 shares of the biopharmaceutical company’s stock valued at $1,053,000 after acquiring an additional 2,171 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Theravance Biopharma by 1.2% during the 4th quarter. Bank of New York Mellon Corp now owns 208,117 shares of the biopharmaceutical company’s stock valued at $5,326,000 after acquiring an additional 2,547 shares during the period. Finally, Quantamental Technologies LLC bought a new position in Theravance Biopharma during the fourth quarter worth $102,000. 84.94% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Read More: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.